IL22 and Guillain-Barre syndrome: In the present study, our results showed that circulating Th1, Th17, and Th22 cells as well as the levels of IL-17 and IL-22 in plasma were obviously elevated in GBS at the acute phase and IVIg treatments could downregulate these cells and their cytokines at the plateau phase of GBS.